Working… Menu

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04702737
Recruitment Status : Recruiting
First Posted : January 11, 2021
Last Update Posted : October 15, 2021
Information provided by (Responsible Party):

Brief Summary:
To evaluate the safety and tolerability of AMG 757 and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Condition or disease Intervention/treatment Phase
Neuroendocrine Prostate Cancer Drug: AMG 757 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
Actual Study Start Date : June 10, 2021
Estimated Primary Completion Date : March 17, 2023
Estimated Study Completion Date : September 12, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Part 1: Dose Exploration
The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
Drug: AMG 757
AMG 757 will be administered as an intravenous (IV) infusion.

Experimental: Part 2: Dose Expansion
Participants will received the recommended phase 2 dose (RP2D) identified in Part 1 (dose exploration) of the study.
Drug: AMG 757
AMG 757 will be administered as an intravenous (IV) infusion.

Primary Outcome Measures :
  1. Number of Participants who Experience One or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Day 1 to 12 months ]
  2. Number of Participants who Experience One or More Treatment-related Adverse Events [ Time Frame: Day 1 to 12 months ]
  3. Number of Participants who Experience a Clinically Significant Change from Baseline in Vital Signs [ Time Frame: Baseline to 12 months ]
  4. Number of Participants who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements [ Time Frame: Baseline to 12 months ]
  5. Number of Participants who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests [ Time Frame: Baseline to 12 months ]
  6. Number of Participants who Experience Dose Limiting Toxicities (DLTs) [ Time Frame: Baseline to 12 months ]

Secondary Outcome Measures :
  1. Objective Response (OR) [ Time Frame: Baseline to 12 months ]
    OR will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications.

  2. Duration of Response (DOR) [ Time Frame: Baseline to 12 months ]
  3. Progression-free Survival (PFS) [ Time Frame: Baseline to 12 months ]
  4. Overall Survival (OS) [ Time Frame: Baseline to 12 months ]
  5. Disease Control Rate (DCR) [ Time Frame: Baseline to 12 months ]
  6. Maximum Serum Concentration (Cmax) of AMG 757 [ Time Frame: Baseline to 12 months ]
  7. Minimum Serum Concentration (Cmin) of AMG 757 [ Time Frame: Baseline to 12 months ]
  8. Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of AMG 757 [ Time Frame: Baseline to 12 months ]
  9. Accumulation Ratio of AMG 757 [ Time Frame: Baseline to 12 months ]
  10. Half-life (t1/2) of AMG 757 [ Time Frame: Baseline to 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant has provided informed consent prior to initiation of any study specific activities/procedures.
  • Men aged ≥ 18 years at time of signing the informed consent.
  • Metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC) defined by histological, immunohistochemistry, or genomic analyses of baseline tumor tissue (by local assessment) or circulating tumor DNA (ctDNA) (by local assessment) as per protocol
  • At least 1 line of prior systemic treatment per protocol.
  • For participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of prostate cancer with neuroendocrine differentiation.
  • Participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of prostate cancer with neuroendocrine differentiation without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analogue therapy during the course of protocol therapy
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per Prostate Cancer Working Group 3 (PCWG3) modifications
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
  • Participants with treated brain metastases are eligible provided they meet defined criteria
  • Adequate organ function as defined in protocol

Exclusion Criteria:

  • History of other malignancy within the past 2 years, with exceptions:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before enrollment and felt to be at low risk for recurrence by the treating physician
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated non-muscle invasive urothelial carcinoma
  • History or presence of hematological malignancies unless curatively treated with no evidence of disease ≥ 2 years
  • Untreated or symptomatic brain metastases and leptomeningeal disease
  • Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone deprivation therapy for hormone refractory prostate is permitted; participants on a stable bisphosphonate or denosumab for ≥ 30 days prior to study day 1 are eligible


  • Participants who received conventional chemotherapy are eligible if at least 14 days have elapsed and if all treatment-related toxicities have resolved to Grade ≤ 1
  • Prior palliative radiotherapy must have been completed at least 7 days before the first dose of AMG 757
  • Participants who received androgen signaling inhibitor are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to Grade ≤ 1

    • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior study day 1
    • Active autoimmune disease requiring systemic treatment within the past 2 years
    • Known positive test for human immunodeficiency virus (HIV) or hepatitis
    • Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade 0 or 1 (with the exception of alopecia or toxicities that are stable and well-controlled)
    • History of hypophysitis or pituitary dysfunction
    • Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
    • Participants on prior DLL3-targeted therapy may be eligible if discussed with Amgen medical monitor prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04702737

Layout table for location contacts
Contact: Amgen Call Center 866-572-6436

Layout table for location information
United States, Georgia
Winship Cancer Institute of Emory University Recruiting
Atlanta, Georgia, United States, 30322
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110-1093
Australia, New South Wales
Chris OBrien Lifehouse Recruiting
Camperdown, New South Wales, Australia, 2050
Australia, Victoria
Peter MacCallum Cancer Centre Recruiting
Melbourne, Victoria, Australia, 3000
Landeskrankenhaus Salzburg Recruiting
Salzburg, Austria, 5020
Universitair Ziekenhuis Gent Recruiting
Gent, Belgium, 9000
Erasmus Medisch Centrum Recruiting
Rotterdam, Netherlands, 3015 GD
Sponsors and Collaborators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen Identifier: NCT04702737    
Other Study ID Numbers: 20200040
First Posted: January 11, 2021    Key Record Dates
Last Update Posted: October 15, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amgen:
De novo or treatment emergent neuroendocrine prostate cancer
Delta-like protein 3 (DLL3)
Non-canonical Notch ligand
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases